Dermapharm's Q4 and Full-Year Results Meet Lower End of Guidance, Fall Short of Street Estimates
Dermapharm Holding SE reported preliminary financial results for the fourth quarter and full year 2025 that landed at the lower boundary of company guidance and slightly below market consensus. Fourth-quarter sales rose 2% year-over-year to €296 million but trailed the company-compiled consensus of €313 million. Adjusted EBITDA improved to €89 mill…